Avanos Medical, Inc.

Avanos Medical, Inc.

21.80
EUR
0.00
(0.00%)
-1.38EPS
564.56MMarket Cap

Total Valuation

EUR

As of March 31, 2026, Avanos Medical, Inc. carries a market capitalization of 564.56M, placing it among publicly traded companies globally. Its enterprise value stands at 627.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap564.56M
Enterprise Value627.54M

Important Dates

Avanos Medical, Inc.'s next confirmed earnings release is scheduled for August 11, 2026.

Earnings Date8/11/2026

Share Statistics

As of March 31, 2026, Avanos Medical, Inc. has 46.67M shares outstanding.

Shares Outstanding46.67M

Valuation Ratios

These figures are as of March 31, 2026. The price-to-sales ratio is 0.91, and the price-to-book ratio stands at 0.83.

PS Ratio0.91
PB Ratio0.83
P/TBV Ratio2.39
P/FCF Ratio17.77
P/OCF Ratio17.68

Enterprise Valuation

These figures are as of March 31, 2026. The EV/Sales ratio of 1.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 627.54M versus a market cap of 564.56M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.01

Financial Position

As of March 31, 2026, Avanos Medical, Inc. maintains a current ratio of 2.48, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.70, indicating elevated leverage, while an interest coverage ratio of -3.26 demonstrates limited ability to service its debt obligations.

Current Ratio2.48
Quick Ratio1.29
Debt / Equity17.70
Debt / EBITDA-5.89
Interest Coverage-3.26

Financial Efficiency

EUR

Over the twelve months ended March 31, 2026, Avanos Medical, Inc. posted a negative return on equity (ROE) of -9.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.90, reflecting losses generated across the asset base. The company generates approximately 274,401.90 in revenue per employee across its workforce of 2,257.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.56 indicates how many times Avanos Medical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-9.18
Return on Assets (ROA)-6.90
Revenue Per Employee274,401.90
Employee Count2,257.00
Inventory Turnover2.56

Taxes

EUR

Over the twelve months ended March 31, 2026, Avanos Medical, Inc. recorded 5.28M in income tax expense. The company reported a pretax loss of -59.09M and -64.36M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax5.28M

Stock Price Statistics

EUR

As of the close on July 24, 2026, Avanos Medical, Inc.'s stock has gained approximately 113.73% over the past 52 weeks. The 50-day moving average sits at 21.62, while the 200-day moving average is 14.65.

52-Week Price Change113.73%
50-Day Moving Average21.62
200-Day Moving Average14.65

Income Statement

EUR

Over the twelve months ended March 31, 2026, Avanos Medical, Inc. generated 619.33M in revenue and converted that into -64.36M in net income, yielding earnings per share of -1.38. EBITDA reached -20.33M, while operating income came in at 12.11M.

Revenue619.33M
Gross Profit309.97M
Operating Income12.11M
Pretax Income-59.09M
Net Income-64.36M
EBITDA-20.33M
EBIT-54.50M
Earnings Per Share (EPS)-1.38

Balance Sheet

EUR

As of March 31, 2026, Avanos Medical, Inc. holds 56.75M in cash and equivalents against 119.73M in total debt, resulting in a net debt position of 28.20M. Total book value stands at 676.59M, with working capital of 167.66M providing operational flexibility.

Cash & Cash Equivalents56.75M
Total Debt119.73M
Net Debt28.20M
Equity (Book Value)676.59M
Book Value Per Share14.50
Working Capital167.66M

Cash Flow

EUR

Avanos Medical, Inc. produced 31.75M in operating cash flow over the twelve months ended March 31, 2026.

Operating Cash Flow31.75M
Free Cash Flow31.75M
FCF Per Share0.68

Margins

Over the twelve months ended March 31, 2026, Avanos Medical, Inc. posted a gross margin of 50.05, reflecting its pricing power and cost economics. The operating margin of 1.96 and net profit margin of -10.39 provide insight into operational efficiency.

Gross Margin50.05
Operating Margin1.96
Pretax Margin-9.54
Profit Margin-10.39
EBITDA Margin-3.28

Dividends & Yields

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 5.63, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.70, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Avanos Medical, Inc. shareholders.

Shareholder Yield1.70
FCF Yield5.63

Scores

As of March 31, 2026, Avanos Medical, Inc. has an Altman Z-Score of 1.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.29